Elanco Animal Health (NYSE:ELAN – Get Free Report) and Quantum Biopharma (NASDAQ:QNTM – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Elanco Animal Health and Quantum Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elanco Animal Health | 1 | 4 | 3 | 0 | 2.25 |
| Quantum Biopharma | 0 | 0 | 0 | 0 | 0.00 |
Elanco Animal Health presently has a consensus price target of $16.43, indicating a potential upside of 35.72%. Given Elanco Animal Health’s stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Quantum Biopharma.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Elanco Animal Health | $4.42 billion | 1.35 | -$1.23 billion | $0.40 | 30.26 |
| Quantum Biopharma | N/A | N/A | -$17.90 million | ($15.41) | -0.22 |
Quantum Biopharma has lower revenue, but higher earnings than Elanco Animal Health. Quantum Biopharma is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Elanco Animal Health and Quantum Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Elanco Animal Health | 4.60% | 6.78% | 3.03% |
| Quantum Biopharma | N/A | -84.21% | -62.63% |
Volatility & Risk
Elanco Animal Health has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Insider & Institutional Ownership
97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Elanco Animal Health beats Quantum Biopharma on 11 of the 13 factors compared between the two stocks.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
About Quantum Biopharma
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
